Protocol Page


	Study ID (Protocol Number)
	CA209-004


	STUDY LOCATIONS*
	Local Institution Washington, District of Columbia 20057 Not yet recruiting	Yale University School Of Medicine New Haven, CT 06520 Recruiting
	Local Institution Pittsburgh, PA 15213-2584 Not yet recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
	STUDY OVERVIEW
	The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.